Innovent Biologics, Inc. (1801) disclosed total product revenue exceeding RMB3.3 billion in the third quarter of 2025, indicating a robust year-on-year increase of approximately 40%. The expansion was attributed to strong performance in both oncology and general biomedicine.

According to the announcement, existing oncology products—including TYVYT® (sintilimab injection) and newly introduced treatments—contributed significantly to overall growth. Meanwhile, the company’s general biomedicine franchise reported rapid revenue expansion, highlighted by accelerated uptake of mazdutide, SINTBILO® (tafolecimab injection), and SYCUME® (teprotumumab N01 injection). Mazdutide also secured a second indication for type 2 diabetes from the National Medical Products Administration of China, potentially benefiting a broader patient population.

Overall, Innovent Biologics, Inc. has 16 approved products, two new drug applications under regulatory review, four late-stage clinical assets, and an additional 15 molecules in early-stage clinical development. The company stated that 2025 marks a pivotal year as it continues to advance its platforms in oncology and general biomedicine with a view toward global innovation. The financial data in the announcement was derived from internal management records, which have not undergone external audit or review.